化合物CDK8-IN-13 T72029

Product Introduction
Bioactivity


英文名: CDK8-IN-13

描述: CDK8-IN-13是一种 CDK8抑制剂（IC50：51.9 nM），具有强效性、选择性和口服活性。CDK8-IN-13能诱导细胞凋亡，降低了 p-STAT1 S727和p-STAT5 S726的表达。CDK8-IN-13表现出抗肿瘤活性。

体外活性: CDK8-IN-13 (compound 43 ; 1, 2.5, 5, 10 µM ; 12 h) decreased p-STAT1 S727 and p-STAT5 S726 expression in HCT-116 cells in a dose-dependent manner.[1] CDK8-IN-13 (0, 1, 5, 10 µM ; 48 h) induced apoptosis in a dose-dependent manner.[1]

体内活性: CDK8-IN-13 (40, 80 mg/kg ; orally ; for 15 days) inhibits tumor growth in a dose-dependent manner in mice.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 112.5 mg/mL (474.2 mM)


关键字: CDK8IN13 | CDK8-IN-13

相关产品: Crebanine | 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one | COTI-2 | dl-Maackiain | Quinacrine dihydrochloride | Phenoxodiol | dBET6 | Pivanex | OsMundacetone | Diatrizoic Acid

相关库: Anti-Cancer Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Active Compound Library | Bioactive Compound Library

化合物CDK8-IN-13 T72029信息由TargetMol中国为您提供，如您想了解更多关于化合物CDK8-IN-13 T72029报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途